<DOC>
	<DOCNO>NCT01120366</DOCNO>
	<brief_summary>The objective study investigate efficacy safety humanize anti-human IL-6 receptor monoclonal antibody tocilizumab ( TCZ ) either monotherapy combination therapy methotrexate ( MTX ) patient inadequate response treatment MTX . Furthermore , patient able achieve control disease activity via therapy , investigate possibility stop TCZ verify safety TCZ restart disease recurrence .</brief_summary>
	<brief_title>Success Tocilizumab RA Patients With Remission Induction Sustained Efficacy After Discontinuation</brief_title>
	<detailed_description>In study , aim prospectively randomly evaluate efficacy change clinical remission joint destruction RA patient treatment TCZ monotherapy ( SWITCH ) combination therapy MTX ( ADD-ON ) , also investigate best therapeutic approach achieve discontinuation .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosed RA accordance 1987 classification criterion ACR Aged 20 75 year inclusive enrolment ( within 2 week start treatment investigational drug ) Treated MTX ≥6 mg/week least 8 week immediately enrolment Rheumatoid arthritis duration ≤10 year DAS28ESR ≥3.2 ( within 2 week start treatment investigational drug ) Having receive thoroughly understood adequate explanation participation study , patient personally voluntarily provide write informed consent Major exclusion criterion : Patients Steinbrocker Class IV . Patients receive leflunomide within 12 week , DMARDs MTX within 8 week , tacrolimus within 4 week 1st TCZ infusion . Patients previously receive biologic DMARDs include TCZ .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>